Intuniv Tablet, Extended Release
Product Images NDC 54092-513

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Intuniv (NDC 54092-513). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Stucture (Intuniv 01)

Chemical structure of guanfacine hydrochloride, the active ingredient in Intuniv. The structure shows a dichlorophenyl group linked to a guanidine moiety. The hydrochloride salt is indicated by HCl.*

FDA Label Image

Figure 1 (Intuniv 02)

A line graph comparing the plasma concentration of guanfacine (ng/mL) over 24 hours between Intuniv 1 mg QD and Tenex 1 mg QD. The x-axis represents time in hours, and the y-axis shows guanfacine plasma concentration. Intuniv shows a slower rise and more sustained concentration compared to Tenex.*

FDA Label Image

Figure 2 (Intuniv 03)

A fold change chart with 90% confidence intervals showing the effects of various CYP3A4/5 inhibitors and inducers, as well as other drugs, on pharmacokinetic parameters Cmax and AUC. Data includes ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate, comparing fold changes relative to a reference.*

FDA Label Image

Figure 3 (Intuniv 04)

A pharmacokinetic plot showing fold changes with 90% confidence intervals for Cmax and AUC of Oral Methylphenidate and Lisdexamfetamine Dimesylate. The x-axis represents change relative to reference, ranging from 0.0 to 2.0, with data points clustered near 1.0, indicating no significant change.*

FDA Label Image

Figure 3 (Intuniv 05)

A line graph comparing treatment failure rates over time in days for placebo and SPD503 groups. The y-axis shows treatment failure percentage, while the x-axis shows time to treatment failure in days, illustrating higher failure rates for the placebo group compared to SPD503 over the study period.*

FDA Label Image

Principal Display Panel (1 mg Tablet Bottle Label)

Intuniv 1 mg extended-release tablets packaging label by Takeda Pharmaceuticals America, Inc. The label states 100 tablets per container with a warning that tablets should not be crushed, chewed, or broken before swallowing. It includes storage instructions and manufacturer information, noting the product is made in Spain.*

FDA Label Image

Principal Display Panel (2 mg Tablet Bottle Label)

Intuniv 2 mg extended-release tablets label from Takeda Pharmaceuticals America, Inc. The label shows 100 tablets per container, with instructions that tablets should not be crushed, chewed, or broken before swallowing. Storage instructions state to keep at 20°C to 25°C with permitted excursions. The product is made in Spain.*

FDA Label Image

Principal Display Panel (3 mg Tablet Bottle Label)

The label for Intuniv (guanfacine) extended-release tablets shows a strength of 3 mg per tablet. The package contains 100 tablets, for prescription use only. It is distributed by Takeda Pharmaceuticals America, Inc. and indicates the tablets should not be crushed, chewed, or broken before swallowing. Storage instructions specify 20°C to 25°C with permitted excursions. Made in Spain.*

FDA Label Image

Principal Display Panel (4 mg Tablet Bottle Label)

Label for Intuniv 4 mg extended-release tablets containing guanfacine HCl. The label indicates 100 tablets per container, prescription only, distributed by Takeda Pharmaceuticals America, Inc. Storage instructions specify 20°C to 25°C (68°F to 77°F) with permitted excursions. Made in Spain.*

FDA Label Image

Principal Display Panel (NDC 54092-520-01)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.